Amy Alexander
Nurse Practitioner · Greensburg, PANPI 1629545512
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,638 of the $41,553 with a category attached, or 81.0%. AbbVie accounts for 95.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $19,292 and has fallen 64.6% since, to $6,825 in 2025. Among nurse practitioner clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 445 payments — averaging $93.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$39K
- Teva Pharmaceuticals USA, Inc.$497
- Alkermes, Inc.$405
- Otsuka America Pharmaceutical, Inc.$198
- Neurocrine Biosciences, Inc.$182
- Sunovion Pharmaceuticals Inc.$137
- plus $660 from 13 others
What the payments were for
- Speaking & faculty fees$33,63881%
- Travel & lodging$2,0995%
- Food & beverage$5,77014%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 310 | $39,473 |
| Teva Pharmaceuticals USA, Inc. | 42 | $497 |
| Alkermes, Inc. | 19 | $405 |
| Otsuka America Pharmaceutical, Inc. | 10 | $198 |
| Neurocrine Biosciences, Inc. | 10 | $182 |
| Sunovion Pharmaceuticals Inc. | 17 | $137 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $133 |
| Axsome Therapeutics, Inc. | 5 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $103 |
| Neos Therapeutics, LP | 3 | $52 |
| Corium, LLC | 4 | $49 |
| Lundbeck LLC | 3 | $48 |
| Avanir Pharmaceuticals, Inc. | 2 | $42 |
| Noven Therapeutics, LLC | 2 | $30 |
| Neuronetics, Inc. | 2 | $27 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $13 |
| OWP Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$35,595
How this compares
$41,553 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 240 | $323,363 |
| IngrezzaValbenazine Tosylate | 13 | $96,943 |
| AustedoDeutetrabenazine | 12 | $82,662 |
| Invega SustennaPaliperidone Palmitate | 14 | $32,835 |
| Aripiprazole | 295 | $16,398 |
| TrintellixVortioxetine Hydrobromide | 20 | $11,681 |
| Chlorpromazine Hcl | 35 | $9,855 |
| XareltoRivaroxaban | 13 | $7,138 |
| Lurasidone Hcl | 17 | $5,584 |
| Buspirone Hcl | 275 | $5,144 |
| Clozapine | 31 | $4,636 |
| Vilazodone Hcl | 43 | $4,578 |
| Duloxetine Hcl | 159 | $4,015 |
| Quetiapine Fumarate | 275 | $3,974 |
| Fluvoxamine Maleate | 127 | $3,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $39,473 | $323,363240 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $182 | $96,94313 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $497 | $82,66212 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $13 | $39,97327 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $103 | $11,68120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Greensburg
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.